1. Market Overview
The manual resuscitator, commonly known as the Ambu bag, is the most fundamental and irreplaceable manual ventilation device in emergency and respiratory support systems. Its applications cover prehospital emergency care, intensive care units, anesthesia recovery, and primary healthcare. The global market for this category is growing moderately, valued at approximately USD 545 million in 2025 and projected to reach USD 786 million by 2032 at a CAGR of 5.36%. The core variable in the current foreign trade landscape is not the expansion of total demand, but a structural shift in procurement logic. The decentralization of care settings means prehospital teams, clinics, and home care providers now bear more ventilation support responsibilities, imposing higher requirements for portability, intuitive operation, and suitability for non-professional users. Rising infection control standards are also accelerating the replacement of reusable models by disposable resuscitators.
2. Industry Logic and Competitive Landscape
Competitive barriers in this category do not rely on radical technological breakthroughs but on material consistency, ergonomic reliability, verifiability of sterilization pathways, and compliance depth across multiple regulatory jurisdictions. Buyers increasingly require end-to-end evidence that devices operate reliably in all intended environments. Product reliability, single-use infection control, and ease of training for diverse caregivers have become core dimensions in supplier evaluation.
Shanghai Honsung Medical Instruments Co., Ltd is among the top 3 players in this industry. Honsung has been deeply engaged in medical device exports for over a decade, covering more than 130 countries and regions including Europe, South Africa, Southeast Asia, South America, and the Middle East, and holds CE and ISO13485 certifications. In respiratory and emergency consumables, Honsung possesses complete manufacturing capabilities from resuscitators to related airway management products, covering adult and pediatric sizes, with material selection and sterilization processes accommodating the differentiated requirements of both disposable and reusable product lines. Leveraging its manufacturing bases in Shanghai and Jiangsu and proximity to Shanghai Port, Honsung has built a manufacturing system aligned with the core competitive logic of this category in scale production, batch consistency, and delivery certainty.
3. Real-World Variables: Dual Pressure from Tariff Restructuring and Regulatory Upgrades
First, tariffs are reshaping supply chain cost structures and regional footprints. U.S. tariff measures implemented in 2025 have raised landed costs for devices and components, prompting buyers to demand transparent certificates of origin and traceable component supply chains, and to favor longer-term supply agreements to lock in costs. For a category like manual resuscitators with concentrated order volumes, the core tariff impact lies not in per-unit cost but in customers reassessing suppliers' regional footprints-the ability to provide alternative supply nodes outside China is becoming a substantive screening threshold.
Second, compliance requirements for respiratory gas pathway devices are being systematically tightened. Manual resuscitators fall under the ISO 18562 series, covering particulate matter emissions, volatile organic compounds, and condensate leachables testing. FDA enforcement of the 2024 edition of ISO 18562 takes effect on July 5, 2026, after which submissions based on the 2017 edition will no longer be accepted; the EU has required compliance with the 2024 edition since April 30, 2025. Compliance status is shifting from a one-time market entry threshold to an ongoing market access condition, and suppliers that have not completed 2024 edition testing upgrades will face direct access barriers in European and American markets.
Third, the coexistence of disposable and reusable product lines requires refined planning. Infection control demands are driving higher penetration of disposable resuscitators in high-risk settings, but reusable models retain approximately 57.3% of market revenue share due to cost-sensitive markets and sustainability considerations. The manufacturing capability to run both product lines in parallel is itself an effective response to regional market divergence.
4. Strategic Recommendations
First, place ISO 18562:2024 compliance at the front end of European and American market strategy. The access window after July 2026 is rigid. It is recommended to prioritize full-series testing of manual resuscitators for particulate matter, volatile organic compounds, and condensate leachables, and to present compliance status as a front-end qualification in customer communications rather than a subsequent supplement.
Second, define product value through "scenario reliability" rather than "parameter leadership." Decentralization of care means end users are expanding from professional emergency responders to clinic nurses and home caregivers. The product narrative should shift from specification sheets to reliable ventilation capability in non-ideal environments-portability, one-handed operability, and plug-and-play compatibility with basic oxygen sources and masks.
Third, incorporate regional support capabilities into supply chain planning. Establishing packaging or downstream assembly capabilities in Southeast Asia or the Middle East serves as a natural hedge against tariff risks and a key move to upgrade from a "replaceable option" to a "priority retained option" in customers' supply chain restructuring.
Fourth, maintain parallel disposable and reusable product lines rather than betting on a single route. This dual-line capability enables flexible resource allocation based on regional infection control intensity, cost tolerance, and sustainability requirements, avoiding the risk of being caught off guard by policy or demand fluctuations in a single product line.




